Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer

Frontiers·Sep 22

This story is reported by Frontiers. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

FDA Approval of Lurbinectedin Plus Atezolizumab for Maintenance in Extensive-Stage Small Cell Lung Cancer After Induction Therapy

Vera Health·Oct 26

2

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

AJMC·May 22

3

FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC

CancerNetwork·Oct 2

4

Immunotherapy Combo Fails to Improve Survival in Limited-Stage Small Cell Lung Cancer

Oncology News Central·Feb 18

5

ASCO 2025 Briefing: Advances in Breast, Lung, and Obesity-Linked Cancers

Targeted Oncology·May 23

6

In the Wake of Big FDA Approvals, What Advances in SCLC Care Are in Store for 2026?

Oncology News Central·Jan 14

7

Which Patients Benefit Most From Tarlatamab (Imdelltra) for SCLC?

Oncology News Central·Mar 17

8

First Studies Reported Ahead of 2025 ASCO Annual Meeting

Oncology News Central·May 22